Congratulations to Gilead for gaining approval for

Congratulations to Gilead for gaining approval for Remdesivir and simultaneously reimagining how we treat serious conditions moving forward. Named “Side Effect Therapeutics” these new drugs will forgo the difficult task of proving they work for an intended condition and will instead just be loaded with side effects.

All of the renal failure and none of the stroke prevention! Now with less A1C control but more bloody stools!!

“Here at Gilead we like to think we’re providing choices so you can live your best life. Why die from your heart attack when you could also die from liver toxicity! Well now anything is possible thanks to the FDA’s groundbreaking approval of Remdesivir for Covid.”

Other companies are rumored to be on the move with similar candidates. Cytodyn, a small pre-revenue biotech located in Vancouver Canada is reportedly working on the next generation of monoclonal antibodies. This new platform therapeutic is called a Monoclonal Lewybody and across multiple indications it will do nothing to address the core disease or its symptoms but will absolutely cause Lewy Body Dementia and Gigantic Eyeball in 97% of patients (p<.0000005).

Overall just a great day for medicine. The future is here. Have a great weekend.